133 related articles for article (PubMed ID: 32012255)
1. Relationship between tumor response at therapy completion and prognosis in patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group.
Lautz TB; Chi YY; Tian J; Gupta AA; Wolden SL; Routh JC; Casey DL; Dasgupta R; Hawkins DS; Rodeberg DA
Int J Cancer; 2020 Sep; 147(5):1419-1426. PubMed ID: 32012255
[TBL] [Abstract][Full Text] [Related]
2. Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.
Rosenberg AR; Anderson JR; Lyden E; Rodeberg DA; Wolden SL; Kao SC; Parham DM; Arndt C; Hawkins DS
Eur J Cancer; 2014 Mar; 50(4):816-23. PubMed ID: 24361229
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group.
Rodeberg DA; Stoner JA; Hayes-Jordan A; Kao SC; Wolden SL; Qualman SJ; Meyer WH; Hawkins DS
J Clin Oncol; 2009 Aug; 27(22):3705-11. PubMed ID: 19470937
[TBL] [Abstract][Full Text] [Related]
4. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
Meza JL; Anderson J; Pappo AS; Meyer WH;
J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
[TBL] [Abstract][Full Text] [Related]
5. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Burke M; Anderson JR; Kao SC; Rodeberg D; Qualman SJ; Wolden SL; Meyer WH; Breitfeld PP;
J Clin Oncol; 2007 Nov; 25(31):4909-13. PubMed ID: 17971587
[TBL] [Abstract][Full Text] [Related]
6. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
Casey DL; Chi YY; Donaldson SS; Hawkins DS; Tian J; Arndt CA; Rodeberg DA; Routh JC; Lautz TB; Gupta AA; Yock TI; Wolden SL
Cancer; 2019 Sep; 125(18):3242-3248. PubMed ID: 31174239
[TBL] [Abstract][Full Text] [Related]
7. The impact of surgical excision in chest wall rhabdomyosarcoma: a report from the Children's Oncology Group.
Hayes-Jordan A; Stoner JA; Anderson JR; Rodeberg D; Weiner G; Meyer WH; Hawkins DS; Arndt CA; Paidas C;
J Pediatr Surg; 2008 May; 43(5):831-6. PubMed ID: 18485948
[TBL] [Abstract][Full Text] [Related]
8. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III.
Wolden SL; Anderson JR; Crist WM; Breneman JC; Wharam MD; Wiener ES; Qualman SJ; Donaldson SS
J Clin Oncol; 1999 Nov; 17(11):3468-75. PubMed ID: 10550144
[TBL] [Abstract][Full Text] [Related]
9. Improved outcome for patients with middle ear rhabdomyosarcoma: a children's oncology group study.
Hawkins DS; Anderson JR; Paidas CN; Wharam MD; Qualman SJ; Pappo AS; Scott Baker K; Crist WM
J Clin Oncol; 2001 Jun; 19(12):3073-9. PubMed ID: 11408504
[TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study.
Vaarwerk B; van der Lee JH; Breunis WB; Orbach D; Chisholm JC; Cozic N; Jenney M; van Rijn RR; McHugh K; Gallego S; Glosli H; Devalck C; Gaze MN; Kelsey A; Bergeron C; Stevens MCG; Oberlin O; Minard-Colin V; Merks JHM
Cancer; 2018 Mar; 124(5):1016-1024. PubMed ID: 29211298
[TBL] [Abstract][Full Text] [Related]
11. Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from intergroup rhabdomyosarcoma studies III and IV.
Pappo AS; Meza JL; Donaldson SS; Wharam MD; Wiener ES; Qualman SJ; Maurer HM; Crist WM
J Clin Oncol; 2003 Feb; 21(4):638-45. PubMed ID: 12586800
[TBL] [Abstract][Full Text] [Related]
12. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
[No Abstract] [Full Text] [Related]
13. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
[TBL] [Abstract][Full Text] [Related]
15. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
Arndt CA; Stoner JA; Hawkins DS; Rodeberg DA; Hayes-Jordan AA; Paidas CN; Parham DM; Teot LA; Wharam MD; Breneman JC; Donaldson SS; Anderson JR; Meyer WH
J Clin Oncol; 2009 Nov; 27(31):5182-8. PubMed ID: 19770373
[TBL] [Abstract][Full Text] [Related]
16. Management and outcomes of chest wall rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Lautz TB; Xue W; Luo LY; Fair D; Qumseya A; Gao Z; Dasgupta R; Rodeberg D; Venkatramani R
Pediatr Blood Cancer; 2023 Jul; 70(7):e30357. PubMed ID: 37070563
[TBL] [Abstract][Full Text] [Related]
17. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
Crist WM; Anderson JR; Meza JL; Fryer C; Raney RB; Ruymann FB; Breneman J; Qualman SJ; Wiener E; Wharam M; Lobe T; Webber B; Maurer HM; Donaldson SS
J Clin Oncol; 2001 Jun; 19(12):3091-102. PubMed ID: 11408506
[TBL] [Abstract][Full Text] [Related]
18. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG.
Donaldson SS; Meza J; Breneman JC; Crist WM; Laurie F; Qualman SJ; Wharam M;
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):718-28. PubMed ID: 11597814
[TBL] [Abstract][Full Text] [Related]
19. Rhabdomyosarcoma of the parotid region occurring in childhood and adolescence. A report from the Intergroup Rhabdomyosarcoma Study Group.
Walterhouse DO; Pappo AS; Baker KS; Parham DM; Anderson JR; Donaldson SS; Paidas CN; Womer RB; Crist WM
Cancer; 2001 Dec; 92(12):3135-46. PubMed ID: 11753993
[TBL] [Abstract][Full Text] [Related]
20. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
; Lager JJ; Lyden ER; Anderson JR; Pappo AS; Meyer WH; Breitfeld PP
J Clin Oncol; 2006 Jul; 24(21):3415-22. PubMed ID: 16849756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
